FDA Grants Clearance for Galapagos' IND Application
Galapagos NV (Euronext & NASDAQ: GLPG) has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application related to the ATALANTA-1 study. This Phase 1/2 multicenter trial is designed to assess the feasibility, safety, and effectiveness of GLPG5101 in patients diagnosed with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).
Overview of GLPG5101
GLPG5101 represents a groundbreaking product candidate, functioning as an autologous CD19 CAR-T cell therapy. It is manufactured through Galapagos’ decentralized cell therapy platform, which enables the delivery of fresh, optimized cells to patients with an impressively short median vein-to-vein time of just seven days.
Aims of the ATALANTA-1 Study
The ATALANTA-1 study has specific objectives outlined in its Phase 1 and Phase 2 components. The primary aim of the Phase 1 segment is to evaluate the safety and initial efficacy of GLPG5101, which will help identify the optimal dose for the subsequent Phase 2 study. Secondary objectives include assessing the efficacy and feasibility of decentralized manufacturing methods for GLPG5101. In the Phase 2 part of the study, the main focus will be on the objective response rate, while secondary objectives will encompass evaluations of the complete response rate, duration of response, progression-free survival, overall survival, safety, pharmacokinetic profiling, and the practical aspects of decentralized manufacturing processes. Each participant in the study will be monitored for a period of 24 months.
Current Progress and Initial Findings
The Phase 1/2 ATALANTA-1 study is currently underway in various European locations. Preliminary data from the study suggests encouraging results for patients with R/R NHL, highlighting the potential of GLPG5101 to make a significant difference in treatment options.
Importance of Decentralized Manufacturing
Galapagos' innovative decentralized cell therapy manufacturing platform seeks to enhance the patient experience by providing better control for physicians and improving operational efficiencies. This platform features the cutting-edge xCellit® workflow management system, which is integrated with a fully closed, automated manufacturing process utilizing advanced technologies like Lonza’s Cocoon®. Additionally, it incorporates a proprietary quality control strategy to maintain the highest standards of product integrity and patient safety.
Galapagos' Commitment to Quality and Innovation
Galapagos is dedicated to addressing significant medical challenges by developing groundbreaking therapies. With a focus on oncology and immunology, the company employs a unified strategy that merges innovative science with technology. Their extensive pipeline includes a variety of therapies, emphasizing small molecules and cell-based innovations. With capabilities that span from laboratory research to patient administration, Galapagos aims to transform healthcare delivery and improve outcomes for both patients and stakeholders.
Understanding Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma (NHL) originates from lymphocytes, which are vital components of the immune system. It can occur at any age but is most commonly found in individuals over 50. Patients often exhibit symptoms such as swollen lymph nodes, fever, and weight loss. Non-Hodgkin lymphoma includes various subtypes, categorized into aggressive and indolent forms, primarily arising from B lymphocytes, but also from T lymphocytes and Natural Killer (NK) cells. Approximately 85% of cases reported in the U.S. involve B-cell lymphoma.
Contact Information for the Company
If you have media inquiries, please reach out to:
Marieke Vermeersch
+32 479 490 603
media@glpg.com
Jennifer Wilson
+44 7444 896759
media@glpg.com
For inquiries related to investors, please contact:
Sofie Van Gijsel
+1 781 296 1143
ir@glpg.com
Sandra Cauwenberghs
+32 495 584 663
ir@glpg.com
Frequently Asked Questions
What is the GLPG5101 therapy?
GLPG5101 is an autologous CD19 CAR-T cell therapy developed by Galapagos, specifically aimed at treating relapsed/refractory non-Hodgkin lymphoma.
What is the objective of the ATALANTA-1 study?
The ATALANTA-1 study is designed to evaluate the safety, efficacy, and manufacturing feasibility of GLPG5101 in potential patients.
What are the expected outcomes of the Phase 1 study?
The primary outcomes will focus on safety and preliminary efficacy, which will help determine the recommended dose for the Phase 2 segment of the study.
How does Galapagos ensure effective manufacturing of CAR-T therapies?
Galapagos employs a decentralized manufacturing platform that enables the delivery of fresh cells within a median vein-to-vein time of seven days.
What is the broader goal of Galapagos as a biotechnology company?
Galapagos aims to develop transformative therapies that address significant unmet medical needs while improving the quality of life for patients.
